<code id='CDE44267F0'></code><style id='CDE44267F0'></style>
      • <acronym id='CDE44267F0'></acronym>
      <center id='CDE44267F0'><center id='CDE44267F0'><tfoot id='CDE44267F0'></tfoot></center><abbr id='CDE44267F0'><dir id='CDE44267F0'><tfoot id='CDE44267F0'></tfoot><noframes id='CDE44267F0'>
      • <optgroup id='CDE44267F0'><strike id='CDE44267F0'><sup id='CDE44267F0'></sup></strike><code id='CDE44267F0'></code></optgroup>
        5. <b id='CDE44267F0'><label id='CDE44267F0'><select id='CDE44267F0'><dt id='CDE44267F0'><span id='CDE44267F0'></span></dt></select></label></b><u id='CDE44267F0'></u>
          <i id='CDE44267F0'><strike id='CDE44267F0'><tt id='CDE44267F0'><pre id='CDE44267F0'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-02 16:01:32 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：16
                                  
                                    
          
                                   
          Alastair Grant/AP
          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 
          advertisement
          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Leqembi, other new Alzheimer’s drugs require better biomarkers
                                
                            
          Next article：  
                                      
                                          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles